Severe Psoriasis – Oral Therapy with a New Retinoid
Abstract
Ro 10–9359 is a retinoic acid derivative, selected for study because of a better tolerance than retinoic acid, shown in animal experiments. Doses of 25 mg b.i.d., 25 mg t.i.d. and 50 mg b.i.d. were administered orally to 27 patients suffering from severe chronic generalized psoriasis. The clinical efficacy was evaluated by means of a new index, psoriasis area and severity index (PASI) based on severity and area of psoriatic lesions. At doses of 25 mg t.i.d. or 50 mg b.i.d. Ro 10–9359 proved to be an extremely potent antipsoriatic drug. A more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4–8 weeks of treatment. This good effect lasted about 5 weeks after treatment. Side effects were frequent, but mostly mild and completely reversible after termination of treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Retinoids have been described as potent anti-inflammatory and protective in pathologies such as chronic obstructive pulmonary disease, rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
“retinoids have been described as potent anti-inflammatory and therefore protective in pathologies such as chronic obstructive pulmonary disease74, rheumatoid arthritis122, psoriasis123, and inflammatory bowel disease124.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [123]
Cites
Introduction to Statistical Analysis.
Latshaw, V. V., Dixon, W. J., & Massey, F. J. (1957) · American Mathematical Monthly · doi:10.2307/2309989 · Cited by 5,083 · see citing works
Bollag, W. (1974) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(74)90112-1 · Cited by 214 · see citing works
Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis
Orfanos, C. E., & Runne, U. (1976) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1976.tb15541.x · Cited by 93 · see citing works
Vitamin-A-Säure bei Hyperkeratosen, epithelialen Tumoren und Akne
Schumacher, A., & Stüttgen, G. (1971) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1110177 · Cited by 64 · see citing works
Stüttgen, G. (1976) · PubMed · Cited by 46 · see citing works
Perorale Applikation zweier Derivate der Vitamin A-S�ure zur internen Psoriasis-Therapie
Runne, U., Orfanos, C. E., & Gartmann, H. (1973) · Archives of Dermatological Research · doi:10.1007/bf00595928 · Cited by 37 · see citing works
Antitumor effect of a new retinoic acid analog
Bollag, W. B. (1974) · Cellular and Molecular Life Sciences · doi:10.1007/bf01923688 · Cited by 30 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A Meta-Analytic Review of the Common-Sense Model of Illness Representations
Hagger, M. S., & Orbell, S. (2003) · Psychology & Health · doi:10.1080/088704403100081321 · Cited by 1,607 · see citing works
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200 · see citing works
Progress in antisense technology
Crooke, S. T. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104408 · Cited by 417 · see citing works
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202646 · Cited by 343 · see citing works
The inflammatory response in mild and in severe psoriasis
Rocha-Pereira, P., Santos-Silva, A., Rebelo, I., Figueiredo, A., Quintanilha, A., & Teixeira, F. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05984.x · Cited by 258 · see citing works
Miele, L., Vallone, S., Cefalo, C., La Torre, G., Di Stasi, C., Vecchio, F. M., D’Agostino, M., Gabrieli, M. L., Vero, V., Biolato, M., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.06.008 · Cited by 249 · see citing works
Depression and anxiety in psoriatic disease: prevalence and associated factors
McDonough, E., Ayearst, R., Eder, L., Chandran, V., Rosen, C. F., Thavaneswaran, A., & Gladman, D. D. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130797 · Cited by 250 · see citing works
The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases
Aletaha, D., & Smolen, J. S. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.09.005 · Cited by 152 · see citing works
Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Ferreira, R., Napoli, J., Enver, T., Bernardino, L., & Ferreira, L. (2020) · Nature Communications · doi:10.1038/s41467-020-18042-2 · Cited by 138 · see citing works
Psychiatric Morbidity in Vitiligo and Psoriasis: A Comparative Study from India
Mattoo, S. K., Handa, S., Kaur, I., Gupta, N., & Malhotra, R. (2001) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2001.tb00004.x · Cited by 108 · see citing works
Glowacka, E., Lewkowicz, P., Rotsztejn, H., & Zalewska, A. (2010) · Advances in Medical Sciences · doi:10.2478/v10039-010-0037-0 · Cited by 60 · see citing works
Mindfulness-Based Interventions for Psoriasis: a Randomized Controlled Trial
D’Alton, P., Kinsella, L., Walsh, O., Sweeney, C., Timoney, I., Lynch, M., O’Connor, M., & Kirby, B. (2019) · Mindfulness · doi:10.1007/s12671-018-0973-5 · Cited by 39 · see citing works
- Authors
- Fredriksson, T., & Pettersson, U.
- Corresponding author
- Fredriksson, T.
- ORCID
- Fredriksson, T.
- Venue
- Dermatologica
- Publisher
- S. Karger AG
- Published
- 2009-10-14
- Volume
- 157
- Issue
- 4
- Pages
- 238-244
- ISSN
- 0011-9075 (ISSN-L)
- 2571-7197
- OpenAlex
- W2067327580
- Cited by
- 2,718
- References
- 7
- Citations by year
- 2026: 54 · 2025: 70 · 2024: 110 · 2023: 96 · 2022: 116 · 2021: 139 · 2020: 110 · 2019: 87 · 2018: 91 · 2017: 113 · 2016: 103 · 2015: 111 · 2014: 116 · 2013: 88 · 2012: 95
- FWCI
- 52.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Dermatologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- severe psoriasis, Ro 10-9359, acitretin, retinoids, oral retinoid therapy, Psoriasis Area and Severity Index, drug tolerability, adverse effects
- MeSH terms
- Administration, Oral, Adult, Chemistry, Chronic Disease, Clinical Trials as Topic, Drug Evaluation, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psoriasis, Tretinoin, Vitamin A, Chemical Phenomena
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
